The increased prevalence of combination products requires a deeper understanding of what regulators expect in different markets and the kinds of studies required. Manufacturers will need to consider how to manage the different regulatory activities, such as usability testing and bridging studies, that are involved with drug and device development. Through a series of panel discussions, we aim to provide valuable insights for regulatory professionals involved in the development and regulation of combination products, ultimately enhancing their understanding and approach to navigating the complex landscape of drug-device development..